drugset
drugset / Trial / NCT03665285

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

NCT03665285 ↗

Phase 1/2 Completed 109 enrolled NextCure, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.

Timeline

Start
2018-10-01
Primary completion
2023-04-11
Completion
2023-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject NC318 Monoclonal antibody 8 mg Intravenous
Subject NC318 Monoclonal antibody 24 mg Intravenous
Subject NC318 Monoclonal antibody 80 mg Intravenous
Subject NC318 Monoclonal antibody 240 mg Intravenous
Subject NC318 Monoclonal antibody 400 mg Intravenous
Subject NC318 Monoclonal antibody 800 mg Intravenous
Subject NC318 Monoclonal antibody 1600 mg Intravenous

Indications

breast cancer cholangiocarcinoma endometrial cancer head and neck squamous cell carcinoma lung cancer melanoma urothelial carcinoma